Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007

Autor: Puig-Vives, M., Pollan, M., Rue, M., Osca-Gelis, G., Saez, M., Izquierdo, A., Marcos-Gragera, R.

Publikováno v: In The Breast October 2012 21(5):646-651

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Autor: Gonzalez-Montes Y; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Rodriguez-Romanos R; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Villavicencio A; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Osca-Gelis G; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain.; Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology (RTH) ICO-ICS, Centre CIBER of Epidemiology and Public Health (CIBERESP), Girona, Spain., González-Bártulos M; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Llopis F; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Clapes V; Clinical Hematology Department, Institut Català d'Oncologia, L'Hospitalet, IDIBELL, Universitat de Barcelona, Hospitalet de LLobregat, Spain., Oriol A; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Barcelona, Spain., Sureda A; Clinical Hematology Department, Institut Català d'Oncologia, L'Hospitalet, IDIBELL, Universitat de Barcelona, Hospitalet de LLobregat, Spain., Escoda L; Hematology Department, Institut Català d'Oncologia, Hospital Joan XXIII, Universitat Rovira i Virgili (URV), Tarragona, Spain., Sarrà J; Hematology Department, Institut Català d'Oncologia, Hospital Joan XXIII, Universitat Rovira i Virgili (URV), Tarragona, Spain., Garzó A; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Lloveras N; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Díez I; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain., Granada I; Hematology Department, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Badalona, Barcelona, Spain., Gallardo D; Hematology Department, Institut Català d'Oncologia, Hospital Dr. Josep Trueta, Institut d'Investigació Biomèdica de Girona (IDIBGI), Josep Carreras Research Institute, Girona, Universitat de Girona, Girona, Spain.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Apr 12; Vol. 14, pp. 1158105. Date of Electronic Publication: 2023 Apr 12 (Print Publication: 2023).

Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor.

Autor: Rubió-Casadevall J; Medical Oncology Department, Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain, Genetic Descriptive, Genetic and Prevention Epidemiology Group, Biomedical Research Institute of Girona (IDIBGI), Spain, School of Medicine, University of Girona (UdG), Spain., Carbó-Bagué A; Medical Oncology Department, Catalan Institute of Oncology, Hospital Josep Trueta, Girona, Spain., Puigdemont M; Genetic Descriptive, Genetic and Prevention Epidemiology Group, Biomedical Research Institute of Girona (IDIBGI), Spain, Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan Department of Health Government of Catalonia, Catalan Institute of Oncology, Girona, Spain, School of Nursery, University of Girona (UdG), Spain., Osca-Gelis G; Genetic Descriptive, Genetic and Prevention Epidemiology Group, Biomedical Research Institute of Girona (IDIBGI), Spain, Tumour Registry of University Hospital Josep Trueta, Catalan Institute of Oncology and Catalan Institute of Health, Girona, Spain., Oliveras G; Pathology Department Hospital Josep Trueta, Catalan Institute of Health, Girona, Spain., Vilar-Coromina N; Genetic Descriptive, Genetic and Prevention Epidemiology Group, Biomedical Research Institute of Girona (IDIBGI), Spain, School of Medicine, University of Girona (UdG), Spain, Dermatology Department, Hospital Josep Trueta, Catalan Institute of Health, Girona, Spain., Ferrer-Fabrega B; Pathology Department, Girona Clinic, Spain., Urban A; Pathology Department, Corporació de Salut del Maresme La Selva, Hospital Sant Jaume de Calella, Spain., Llobet-Roma M; Pathology Department, Serveis de Salut Integrats Baix Empordà, Palamos Hospital, Spain., Martín-Romero F; Pathology Department, Fundació Salut Emporda, Figueres Hospital, Spain., Perez-Bueno F; Pathology Department Hospital Josep Trueta, Catalan Institute of Health, Girona, Spain., Marcos-Gragera R; Genetic Descriptive, Genetic and Prevention Epidemiology Group, Biomedical Research Institute of Girona (IDIBGI), Spain, School of Medicine, University of Girona (UdG), Spain, Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan Department of Health Government of Catalonia, Catalan Institute of Oncology, Girona, Spain.

Publikováno v: European journal of dermatology : EJD [Eur J Dermatol] 2021 Oct 01; Vol. 31 (5), pp. 616-622.

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Autor: Van Der Zwan, Jan Maarten, Trama, Annalisa, Otter, Renã©e, Larraã±aga, Nerea, Tavilla, Andrea, Marcos-gragera, Rafael, Dei Tos, Angelo Paolo, Baudin, Eric, Poston, Graeme, Links, Thera, Zielonke, N., Van Eycken, E., Sundseth, H., Hedelin, G., Faivre, JULIEN YVES STEPHAN, Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, Marco, Bara, S., Ganry, O., Grosclaude, P., Holleczek, B., Geissler, J., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, Silvia, Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, Angelo, Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., LA ROSA, FEDERICA IRENE, Contiero, P., Fiore, A., Gatta, G., Casali, P. G., Gronchi, A., Ruzza, Marta, Sowe, S., De Angelis, R., Dei Tos, A. P., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic-zakelj, M., Mateos, A., Martã­nez, R., Torrella-ramos, A., Osca-gelis, G., Chirlaque, M. D., Moreno, C., Galceran, J., Martinez-garcia, C., Melchor, J. M., Sã¡nchez, M. J., Virizuela-echaburu, J. A., Cervantes, A., Adolfsson, J., Lambe, M., Mã¶ller, T. R., Ringborg, U., Jundt, G., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Lutz, J. M., Visser, O., Siesling, S., Coebergh, J. W. W., Greenberg, D. C., Wilkinson, Robert John Duncan, Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., White, C.

Publikováno v: European Journal of Cancer, 49(11), 2565-2578. ELSEVIER SCI LTD
European Journal of Cancer, Vol. 49, No 11 (2013) pp. 2565-2578

Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs).A large population-based database (including cancer patients diagnosed from 1978 to 200

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40c4f830103b44280b23162c6577d820
http://hdl.handle.net/11577/3243866

Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020.

Autor: Aslani, Armin¹, Morsali, Soroush^2,3, Mousavi, Seyed Ehsan^1,4 drehsanmousavii@gmail.com, Choupani, Samireh⁵, Yekta, Zahra⁶, Nejadghaderi, Seyed Aria^7,8 ariang20@gmail.com

Publikováno v: Scientific Reports. 9/3/2024, Vol. 14 Issue 1, p1-17. 17p.